Home > Gastroenterology > DDW 2022 > IBD > Positive outcomes for etrasimod in UC

Positive outcomes for etrasimod in UC

Presented By
Prof. William J Sandborn, University of California San Diego, CA, USA
Conference
DDW 2022
Trial
Phase 3, ELEVATE UC 12; ELEVATE UC 52
Doi
https://doi.org/10.55788/86eb89a5
The small molecule etrasimod was evaluated in 2 phase 3 trials with a duration of 12 and 52 weeks in patients with moderate-to-severe ulcerative colitis (UC). Significant better results were seen in the etrasimod groups which included about 4 times higher clinical remission rates at year 1. Etrasimod is a selective sphingosine-1-phospate-receptor modulator that is currently evaluated for various immuno-inflammatory indications. Newly reported was data on ELEVATE UC 52 (NCT03945188) and ELEVATE UC 12 (NCT03996369), 2 phase 3 trials on UC that were conducted by Prof. William J Sandborn (University of California San Diego, CA, USA) and colleagues [1]. Participating adults in both studies suffered from moderate-to-severe UC defined by activity measures of a modified Mayo...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on